{"id":"ato","safety":{"commonSideEffects":[{"rate":"25-30","effect":"Differentiation syndrome (APL differentiation syndrome)"},{"rate":"null","effect":"QT prolongation"},{"rate":"null","effect":"Leukocytosis"},{"rate":"null","effect":"Hepatotoxicity"},{"rate":"null","effect":"Neuropathy"},{"rate":"null","effect":"Hyperglycemia"}]},"_chembl":{"chemblId":"CHEMBL456550","moleculeType":"Small molecule","molecularWeight":"414.34"},"_dailymed":{"setId":"b687ba81-cb24-bbdf-5dd9-ab0e53dd480b","title":"ATORVASTATIN CALCIUM TABLET, FILM COATED [AVPAK]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ATO works through multiple mechanisms including induction of cellular differentiation, triggering apoptosis via mitochondrial pathways, and generation of reactive oxygen species in leukemic blasts. It is particularly effective in acute promyelocytic leukemia (APL) where it targets the PML-RARA fusion protein, leading to degradation of the abnormal fusion protein and restoration of normal hematopoietic differentiation.","oneSentence":"Arsenic trioxide induces differentiation and apoptosis of leukemic cells, particularly in acute promyelocytic leukemia.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:25.290Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute promyelocytic leukemia (APL), including newly diagnosed and relapsed/refractory disease"}]},"trialDetails":[{"nctId":"NCT02339740","phase":"PHASE3","title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-07-21","conditions":"Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA","enrollment":158},{"nctId":"NCT07348107","phase":"PHASE1","title":"ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Daniel Breadner","startDate":"2026-02-15","conditions":"Advanced Pancreatic Ductal Adenocarcinoma","enrollment":10},{"nctId":"NCT07296445","phase":"PHASE3","title":"A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)","status":"NOT_YET_RECRUITING","sponsor":"SDK Therapeutics, Inc.","startDate":"2026-01","conditions":"Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA","enrollment":120},{"nctId":"NCT07280468","phase":"PHASE4","title":"Endotype DIrected Treatment for OSA in Down Syndrome","status":"NOT_YET_RECRUITING","sponsor":"University of Arizona","startDate":"2026-02-01","conditions":"Obstructive Sleep Apnea (OSA), Down Syndrome","enrollment":200},{"nctId":"NCT02938858","phase":"","title":"French Registry of First-line Treatment of Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2015-10","conditions":"Acute Promyelocytic Leukemia","enrollment":400},{"nctId":"NCT06882031","phase":"PHASE1","title":"Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"SDK Therapeutics, Inc.","startDate":"2025-03-11","conditions":"Acute Promyelocytic Leukemia (APL)","enrollment":12},{"nctId":"NCT07187505","phase":"NA","title":"Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anhui Medical University","startDate":"2025-07-01","conditions":"Acute Promyelocytic Leukemia (APL)","enrollment":28},{"nctId":"NCT05761444","phase":"PHASE4","title":"Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2023-07-26","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":137},{"nctId":"NCT04115878","phase":"PHASE2","title":"Medications for Obstructive Sleep Apnea In Children With Down Syndrome","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2020-10-21","conditions":"Obstructive Sleep Apnea, Down Syndrome","enrollment":22},{"nctId":"NCT06670222","phase":"PHASE1","title":"Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)","status":"RECRUITING","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2025-07-22","conditions":"Low-risk Myelodysplastic Syndromes","enrollment":24},{"nctId":"NCT06778187","phase":"PHASE2","title":"Oral-ATO for TP53-mutated Myeloid Malignancies","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-02-07","conditions":"Acute Myeloid Leukemia, Myelodysplastic Neoplasm, Chronic Myelomonocytic Leukemia","enrollment":30},{"nctId":"NCT03031249","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia","status":"ENROLLING_BY_INVITATION","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2017-02-08","conditions":"AML","enrollment":80},{"nctId":"NCT03503864","phase":"PHASE2","title":"Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yang Li","startDate":"2017-06-12","conditions":"Neuroblastoma","enrollment":80},{"nctId":"NCT04113551","phase":"","title":"A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-10-01","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":17418},{"nctId":"NCT06933394","phase":"PHASE2","title":"Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-05-01","conditions":"Neuroblastoma","enrollment":92},{"nctId":"NCT02688140","phase":"PHASE3","title":"Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2016-06","conditions":"Acute Promyelocytic Leukemia","enrollment":135},{"nctId":"NCT05933603","phase":"PHASE2","title":"Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2023-09-29","conditions":"Obstructive Sleep Apnea, Down Syndrome","enrollment":36},{"nctId":"NCT06544109","phase":"PHASE2, PHASE3","title":"Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients","status":"ENROLLING_BY_INVITATION","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-08-01","conditions":"Acute Promyelocytic Leukemia","enrollment":98},{"nctId":"NCT03318016","phase":"PHASE1","title":"Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2017-12-15","conditions":"Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia","enrollment":5},{"nctId":"NCT06450145","phase":"NA","title":"Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant APL","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2024-05-01","conditions":"Tumour","enrollment":15},{"nctId":"NCT04793919","phase":"PHASE2","title":"Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia","status":"RECRUITING","sponsor":"Associazione Italiana Ematologia Oncologia Pediatrica","startDate":"2019-10-09","conditions":"Acute Promyelocytic Leukemia","enrollment":89},{"nctId":"NCT04996030","phase":"PHASE1","title":"A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia","status":"SUSPENDED","sponsor":"Syros Pharmaceuticals","startDate":"2021-09-17","conditions":"Acute Promyelocytic Leukemia","enrollment":16},{"nctId":"NCT04897490","phase":"","title":"RWE of 1st Line Treatment With ATO/ATRA for Adult APL","status":"RECRUITING","sponsor":"Grupo Argentino de Tratamiento de la Leucemia Aguda","startDate":"2021-03-01","conditions":"Promyelocytic Leukemia, Adult Acute","enrollment":50},{"nctId":"NCT06088030","phase":"PHASE2","title":"Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer","status":"RECRUITING","sponsor":"Yang Li","startDate":"2023-12-13","conditions":"Pediatric Cancer, Li-Fraumeni Syndrome, p53 Mutations","enrollment":50},{"nctId":"NCT03377725","phase":"PHASE3","title":"Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)","status":"WITHDRAWN","sponsor":"Li Junmin","startDate":"2018-03-20","conditions":"Myelodysplastic Syndromes, P53 Mutation","enrollment":""},{"nctId":"NCT05721872","phase":"PHASE1, PHASE2","title":"Efficacy, Tolerability and Safety of Intravenous D-VC With ATO in Patients With Advanced/Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Nazarbayev University","startDate":"2023-02-15","conditions":"Colorectal Cancer, Metastatic Colorectal Cancer","enrollment":38},{"nctId":"NCT03855371","phase":"PHASE1","title":"Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2018-01-10","conditions":"P53 Mutation, Myeloid Malignancy, MDS","enrollment":5},{"nctId":"NCT05497310","phase":"PHASE1, PHASE2","title":"Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL","status":"UNKNOWN","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2022-07-01","conditions":"Promyelocytic Leukemia","enrollment":15},{"nctId":"NCT00866918","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2009-03-09","conditions":"Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm","enrollment":106},{"nctId":"NCT00482833","phase":"PHASE3","title":"Phase III Trial in Acute Promyelocytic Leukemia Patients","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2007-08","conditions":"Leukemia","enrollment":276},{"nctId":"NCT02200978","phase":"PHASE4","title":"A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia","status":"COMPLETED","sponsor":"South China Children's Leukemia Group","startDate":"2011-09","conditions":"Childhood Acute Promyelocytic Leukemia","enrollment":176},{"nctId":"NCT02966301","phase":"PHASE2","title":"Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide","status":"COMPLETED","sponsor":"Medsenic","startDate":"2016-12","conditions":"Chronic Graft-Versus-Host Disease, Immune System Diseases","enrollment":21},{"nctId":"NCT05297123","phase":"PHASE1","title":"Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2019-02-03","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT03202901","phase":"NA","title":"Accute Effect of B-Turmactive Both on Mild and Moderate Knee Pain on Healthy Volunteers","status":"COMPLETED","sponsor":"Technological Centre of Nutrition and Health, Spain","startDate":"2017-09-19","conditions":"Knee Injuries, Inflammation Knees","enrollment":70},{"nctId":"NCT03751917","phase":"","title":"Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia","status":"UNKNOWN","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2020-04-14","conditions":"Acute Promyelocytic Leukemia","enrollment":100},{"nctId":"NCT01404949","phase":"PHASE2","title":"Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-07","conditions":"Acute Promyelocytic Leukemia","enrollment":17},{"nctId":"NCT02899169","phase":"PHASE3","title":"Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2016-09-01","conditions":"Acute Promyelocytic Leukemia","enrollment":110},{"nctId":"NCT02190695","phase":"PHASE2","title":"Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS","status":"COMPLETED","sponsor":"Fox Chase Cancer Center","startDate":"2013-04-01","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia","enrollment":92},{"nctId":"NCT01470248","phase":"PHASE2","title":"Study of Arsenic Trioxide in Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2011-08","conditions":"Lung Cancer, Cancer of Lung, Pulmonary Cancer","enrollment":20},{"nctId":"NCT03096496","phase":"","title":"Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy","status":"UNKNOWN","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2017-03-27","conditions":"Acute Promyelocytic Leukemia","enrollment":161},{"nctId":"NCT00469209","phase":"PHASE1, PHASE2","title":"Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-06","conditions":"Myeloma","enrollment":60},{"nctId":"NCT00234000","phase":"PHASE1","title":"Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2007-02","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":1},{"nctId":"NCT00274820","phase":"PHASE2","title":"Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2005-10","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes","enrollment":15},{"nctId":"NCT00275067","phase":"PHASE1, PHASE2","title":"Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery","status":"UNKNOWN","sponsor":"Northwestern University","startDate":"2005-05","conditions":"Brain and Central Nervous System Tumors","enrollment":50},{"nctId":"NCT00413166","phase":"PHASE2","title":"All-trans Retinoic Acid, and Arsenic +/- Idarubicin","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-12","conditions":"Acute Promyelocytic Leukemia","enrollment":78},{"nctId":"NCT03381781","phase":"PHASE2","title":"Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations","status":"UNKNOWN","sponsor":"Li Junmin","startDate":"2018-03","conditions":"Acute Myeloid Leukemia, P53 Mutation","enrollment":100},{"nctId":"NCT00572065","phase":"EARLY_PHASE1","title":"Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2008-02-29","conditions":"Myelofibrosis","enrollment":21},{"nctId":"NCT00504101","phase":"PHASE1","title":"Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2007-06","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":""},{"nctId":"NCT00449137","phase":"PHASE1","title":"Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment","status":"COMPLETED","sponsor":"University of Miami","startDate":"2005-06","conditions":"Colorectal Cancer","enrollment":13},{"nctId":"NCT01738360","phase":"PHASE2","title":"Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)","status":"TERMINATED","sponsor":"Nantes University Hospital","startDate":"2013-07","conditions":"Systemic Lupus","enrollment":11},{"nctId":"NCT00274781","phase":"PHASE2","title":"Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2004-02","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":30},{"nctId":"NCT00201695","phase":"PHASE2","title":"Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2004-07","conditions":"Multiple Myeloma","enrollment":12},{"nctId":"NCT01797237","phase":"PHASE4","title":"Outcome Comparison Between PFNA and InterTAN","status":"UNKNOWN","sponsor":"Peifu Tang","startDate":"2012-10","conditions":"Intertrochanteric Fracture","enrollment":60},{"nctId":"NCT00504764","phase":"PHASE4","title":"Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2007-07","conditions":"Acute Promyelocytic Leukemia","enrollment":60},{"nctId":"NCT00184054","phase":"PHASE2","title":"Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2002-04","conditions":"Acute Myelogenous Leukemia","enrollment":11},{"nctId":"NCT00590603","phase":"PHASE1","title":"Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Duke University","startDate":"2008-07","conditions":"Multiple Myeloma","enrollment":25},{"nctId":"NCT00258245","phase":"PHASE1","title":"Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2005-05","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":5},{"nctId":"NCT00621023","phase":"PHASE2","title":"Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Duke University","startDate":"2007-11","conditions":"Myelodysplastic Syndrome","enrollment":7},{"nctId":"NCT00803530","phase":"PHASE2","title":"Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes","status":"TERMINATED","sponsor":"Fondazione Italiana Sindromi Mielodisplastiche-ETS","startDate":"2005-09","conditions":"Myelodysplastic Syndromes","enrollment":55},{"nctId":"NCT00720564","phase":"PHASE1","title":"Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2008-04","conditions":"Brain and Central Nervous System Tumors","enrollment":18},{"nctId":"NCT00850304","phase":"PHASE2","title":"Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2007-10","conditions":"Leukemia, Myeloid, Acute","enrollment":10},{"nctId":"NCT00790530","phase":"NA","title":"Automated Telephone Outreach With Speech Recognition to Improve Diabetes Care: A Randomized Controlled Study","status":"COMPLETED","sponsor":"Harvard Pilgrim Health Care","startDate":"2006-06","conditions":"Diabetes Mellitus","enrollment":1200},{"nctId":"NCT00517712","phase":"PHASE2, PHASE3","title":"Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia","status":"UNKNOWN","sponsor":"Christian Medical College, Vellore, India","startDate":"2004-06","conditions":"Acute Promyelocytic Leukemia","enrollment":400}],"_emaApprovals":[],"_faersSignals":[{"count":16,"reaction":"ACUTE PROMYELOCYTIC LEUKAEMIA DIFFERENTIATION SYNDROME"},{"count":13,"reaction":"ELECTROCARDIOGRAM QT PROLONGED"},{"count":8,"reaction":"LEUKAEMIA RECURRENT"},{"count":8,"reaction":"MYELODYSPLASTIC SYNDROME TRANSFORMATION"},{"count":7,"reaction":"LEUKOPENIA"},{"count":6,"reaction":"INFECTION"},{"count":5,"reaction":"PYREXIA"},{"count":4,"reaction":"ACUTE PROMYELOCYTIC LEUKAEMIA"},{"count":4,"reaction":"HAEMATOTOXICITY"},{"count":4,"reaction":"HAEMORRHAGE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["As2O3","arsenic trioxide"],"phase":"marketed","status":"active","brandName":"ATO","genericName":"ATO","companyName":"South China Children's Leukemia Group","companyId":"south-china-children-s-leukemia-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Arsenic trioxide induces differentiation and apoptosis of leukemic cells, particularly in acute promyelocytic leukemia. Used for Acute promyelocytic leukemia (APL), including newly diagnosed and relapsed/refractory disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}